OMERS ADMINISTRATION Corp Has $2.76 Million Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• OMERS ADMINISTRATION Corp increased its stake in United Therapeutics Corporation by 22.4%, acquiring an additional 1,634 shares, raising its total holdings to 8,944 shares valued at approximately $2.76 million.
• United Therapeutics reported $6.41 earnings per share for the most recent quarter, missing expectations, with a net margin of 40.36% and revenue of $798.60 million.
• Analyst ratings for United Therapeutics vary, with nine analysts giving it a Buy rating and a consensus price target of $382.00, despite some recent downgrades from firms like Bank of America and JPMorgan Chase & Co.

OMERS ADMINISTRATION Corp boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 22.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,944 shares of the biotechnology company's stock after acquiring an additional 1,634 shares during the period. OMERS ADMINISTRATION Corp's holdings in United Therapeutics were worth $2,757,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Hohimer Wealth Management LLC raised its position in shares of United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after purchasing an additional 37 shares during the period. Applied Finance Capital Management LLC grew its stake in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after acquiring an additional 40 shares during the period. Headlands Technologies LLC raised its position in shares of United Therapeutics by 1.5% in the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock valued at $828,000 after purchasing an additional 40 shares during the period. Cadence Bank boosted its position in shares of United Therapeutics by 1.2% in the first quarter. Cadence Bank now owns 3,963 shares of the biotechnology company's stock valued at $1,222,000 after acquiring an additional 47 shares during the period. Finally, Dunhill Financial LLC raised its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer owned 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,681 shares of company stock worth $25,807,469. 10.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on UTHR. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Jefferies Financial Group boosted their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research report on Tuesday. Bank of America boosted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $403.54.

United Therapeutics Stock Up 32.8%

Shares of NASDAQ UTHR traded up $100.05 during mid-day trading on Tuesday, hitting $404.81. 3,141,718 shares of the company were exchanged, compared to its average volume of 547,665. The stock has a 50 day simple moving average of $299.03 and a 200-day simple moving average of $304.77. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $436.95. The firm has a market cap of $18.26 billion, a price-to-earnings ratio of 15.80, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm's quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $5.85 EPS. Analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.